ibandronic acid

Action and Spectrum

Actions and Spectrum:  

Actions:  

Ibandronic acid stops bone breakdown, boosts bone density, and lowers fracture risk without affecting bone creation. 

Spectrum:  

Ibandronic acid treats high calcium levels in cancer and osteoporosis in postmenopausal women, maintaining normal levels for up to 36 days in severe cancer cases. In postmenopausal women, it lowers fracture risk and bone turnover. 

Drug Interaction

Adverse Reaction

Frequency not defined  

Decreased appetite  

Myalgia  

Dizziness  

Gastritis  

Headache  

Arthralgia  

Flatulence  

Muscle cramps  

Nausea  

Black Box Warning

Black Box Warning: 

 Avoid IBANDRONIC ACID if allergic to its components, have esophageal issues, cannot stand or sit upright for 60 minutes, or have low blood calcium. Inform your doctor about digestive issues, swallowing problems, kidney/liver problems, malabsorption syndrome, and dental plans. Potential side effects include low blood calcium, esophageal problems, severe jaw issues (osteonecrosis), bone/muscle pain, and uncommon thigh bone fractures. Keep your doctor informed about health and medications to prevent potential interactions or side effects. 

Contraindication / Caution

Contraindication/Caution:  

Contraindications  

Hypersensitivity  

Pediatrics  

Galactosemia  

Lactose intolerance  

Glucose-galactose malabsorption  

Pregnancy & breastfeeding  

Hypocalcemia  

Cautions  

Renal impairment  

Hepatic impairment  

Drug interactions (NSAIDS, chemotherapy, corticosteroids)  

Hypocalcemia  

Prolonged oesophageal transit time  

Dysphagia  

Osteonecrosis  

Pregnancy / Lactation

Pregnancy consideration:   

Pregnancy category: C  

Breastfeeding warnings:   

No data is available regarding the excretion of drug in breast milk.  

Pregnancy category:  

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.  

<b>Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  

Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.     

Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.     

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.     

Category N: No data is available for the drug under this category.  

Pharmacology

Pharmacology:  

Ibandronic acid is useful for cancer patients with bone metastases and women with osteoporosis, preventing fractures.  

Pharmacodynamics:  

Ibandronic acid stops bone breakdown, boosts bone density, and lowers fracture risk without affecting bone creation. 

Pharmacokinetics:  

Absorption  

The bioavailability is >0.63% 

Peak effect is reached in less than 1 hour. 

Distribution  

60% of protein bound.  

Volume of distribution: 360 L. 

Elimination and Excretion  

Half-life ranges from 10 to 60 hours.  

The drug is excreted through the kidneys, with a total body clearance of 130 mL/min and renal clearance of 88 mL/min. 

Adminstartion

Administration:  

The route of administration is oral 

Patient Information Leaflet

Patient information leaflet  

Generic Name: ibandronic acid  

Pronounced: eye-BAN-droh-nik AS-id   

Why do we use ibandronic acid?  

The main indication for ibandronic acid use in postmenopausal women is osteoporosis.
Bone metastases from cancer patients can benefit from ibandronic acid.